Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The H4-Index of Expert Review of Pharmacoeconomics & Outcomes Research is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy166
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications47
Distinguishing features in the assessment of mHealth apps37
Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic36
Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses32
Organizational measures aiming to combat COVID-19 in the Russian Federation: the first experience32
Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review28
Tools to assess the quality of life in patients with Parkinson’s disease: a systematic review28
First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China26
Health-related quality of life in patients with chronic kidney disease25
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments23
Evaluation instruments for executive functions in children and adolescents: a systematic review19
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review17
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease16
Valuing health outcomes: developing better defaults based on health opportunity costs16
Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia15
0.042789936065674